Champions Oncology, Inc.
NASDAQ:CSBRBiotechnology
-$0.08 today
- Market cap
- $61.80M
- Beta
- 0.40
- P/E (TTM)
- -41.0
- EPS (TTM)
- -$0.16
Volume 0.01M
Average 0.01M
CSBR Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Champions Oncology, Inc.NASDAQ: CSBR
Net Income · Q3 FY2026 · quarter ended Jan 2026
Net income turns negative
Q3 FY2026 net income was -$278K, compared with $4.5M a year earlier. Trailing-twelve-month net income was -$2.34M. Over 3 fiscal years it compounded at +104.7% a year.
Context
- Net income amounted to 8.3% of revenue in FY2025, down 6.3 pp from a year earlier.
- Net income increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 1 analysts of $1.66M (-64.7%) for the fiscal year ending Apr 2026, a slowdown from the +164.6% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJan 2026
- -$278K-217.8% QoQ
- Last fiscal yearApr 2025
- $4.7M+164.6% YoY
- LTMJan 2026
- -$2.34M-136.5% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -106.2% | -62.1% | +44.1 pp |
| 1 year | +164.6% | -64.7% | -229.3 pp |
| 3-year CAGR | +104.7% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- 4.7M USD
- Year-over-year change
- +164.6%
- 4-year CAGR
- +93.7%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-04-30 | 4.7M | +164.6% |
| FY2024 | 2024-04-30 | (7.28M) | -36.4% |
| FY2023 | 2023-04-30 | (5.34M) | -1073.5% |
| FY2022 | 2022-04-30 | 548K | +64.1% |
| FY2021 | 2021-04-30 | 334K | — |
Net Income vs competitors
How CSBR compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -136.5% is the lowest of 9, against a peer median of +0.1%.
- Net income amounts to 4.0% of revenue for CSBR, versus a peer median of 4987.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $153.6M USD | -37.4% | +17.0% | 154.2% | |
| LTM Mar 2026 | $110M USD | +489.6% | — | — | |
ARTVArtiva Biotherapeutics, Inc. | LTM Mar 2026 | $87.07M USD | +21.4% | +12.6% | — |
| FY2025 | $55.48M USD | +255.0% | -21.8% | 86687.5% | |
| LTM Mar 2026 | $49.87M USD | -29.4% | -21.8% | 4987.4% | |
IMAImageneBio Inc | LTM Mar 2026 | $45.07M USD | +8.1% | -8.7% | — |
KLRSKalaris Therapeutics Inc | LTM Mar 2026 | $44.1M USD | — | +41.0% | — |
| LTM Mar 2026 | €41.2M EUR | -7.9% | +14.1% | 140477.1% | |
| LTM Mar 2026 | $9.47M USD | -39.5% | — | 40.9% | |
| LTM Jan 2026 | $2.34M USD | -136.5% | +104.7% | 4.0% | |
| Peer median (excluding CSBR) | — | +0.1% | +12.6% | 4987.4% | |
Competitors are the stored peer set for CSBR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Apr 2021 | FY2022 Apr 2022 | FY2023 Apr 2023 | FY2024 Apr 2024 | FY2025 Apr 2025 |
|---|---|---|---|---|---|
| Net Income | 334K | 548K | (5.34M) | (7.28M) | 4.7M |
| Depreciation & Amortization | 1.18M | 1.63M | 2.25M | 1.87M | 1.64M |
| Deferred Income Tax | 49K | 0 | 1M | 0 | 0 |
| Stock-Based Compensation | 598K | 912K | 864K | 1.12M | 654K |
| Change in Working Capital | (4.17M) | 2.34M | 4.23M | (3.82M) | (621K) |
| Accounts Receivables | (2.27M) | (2.82M) | 1.31M | (1.99M) | (1.44M) |
| Inventory | (1.1M) | 0 | 0 | 0 | 0 |
| Accounts Payables | (1.25M) | 974K | 2.47M | 465K | (1.75M) |
| Other Working Capital | 441K | 4.18M | 470K | (2.3M) | 2.56M |
| Other Non-Cash Items | 323K | 1.07M | 952K | 1.98M | 1.01M |
| Operating Cash Flow | (1.68M) | 6.5M | 3.96M | (6.14M) | 7.39M |
| Capital Expenditures | (3.28M) | (2.38M) | (2.87M) | (836K) | (389K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 112K | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (3.17M) | (2.38M) | (2.87M) | (836K) | (389K) |
| Debt Repayment | (174K) | 0 | 0 | (146K) | (150K) |
| Common Stock Issued | 1.37M | 207K | 85K | 253K | 320K |
| Common Stock Repurchased | 0 | 0 | (74K) | (634K) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 85K | 253K | 0 |
| Financing Cash Flow | 1.2M | 207K | 11K | (527K) | 170K |
| Effect of Forex Changes | 0 | 0 | 17K | 0 | 0 |
| Net Change in Cash | (3.66M) | 4.32M | 1.11M | (7.5M) | 7.17M |
| Free Cash Flow | (4.96M) | 4.11M | 1.08M | (6.97M) | 7M |
Champions Oncology, Inc.
NASDAQ:CSBR
Intrinsic Alpha fair value
Locked
Current Price
$4.44
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.